RhumbLine Advisers
ATOS icon

RhumbLine Advisers’s Atossa Therapeutics ATOS Stock Holding History

RhumbLine Advisers’s Portfolio ATOS Stock Details ATOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-8,657
Closed -$87.4K – 4149
2025
Q1 		$87.4K Buy
8,657
+509
+6% +$6.18K ﹤0.01% 3436
2024
Q4 		$115K Sell
8,148
-55
-0.7% -$1.07K ﹤0.01% 3438
2024
Q3 		$187K Sell
8,203
-805
-9% -$16.3K ﹤0.01% 3269
2024
Q2 		$161K Buy
+9,008
New +$199K ﹤0.01% 3346
2022
Q2 		– Sell
-9,460
Closed -$177K – 3103
2022
Q1 		$177K Buy
9,460
+685
+8% +$13.9K ﹤0.01% 2785
2021
Q4 		$211K Sell
8,775
-224
-2% -$8.2K ﹤0.01% 2819
2021
Q3 		$440K Buy
8,999
+308
+4% +$17.9K ﹤0.01% 2604
2021
Q2 		$824K Buy
+8,691
New +$460K ﹤0.01% 2333

Other funds holding ATOS

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Ameriprise
Ameriprise Minneapolis, Minnesota $431B AUM 30.22% 1-Year Est. Return
BlackRock
BlackRock New York $5.7T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $134B AUM 35.51% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Jane Street
Jane Street New York $93.1B AUM 61.18% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $70.4B AUM 20.22% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $564B AUM 30.12% 1-Year Est. Return